Abstract
Nevirapine is a non-nucleoside reverse transcriptase inhibitor specific for HIV-1.1,2 This review will focus on some clinically important aspects of the pharmacology and virology of nevirapine, as well as adverse events and the results of some completed clinical studies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Merluzzi VJ. Hargrave KD, Labadia M. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990;. 250; 1411–3.
Koup RA, Merluzzi VJ, Hargrave KD, et al. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J Infect Dis 1991; 163: 966–70.
Nevirapine Investigator’s Brochure. Boerhinger-Ingelheim Pharmaceuticals Inc. 1994.
Richman D, Shill CK, Lowy I, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991, 88: 11241–5.
Mellors JW, Dutschman GE, Im GJ, et al. In vitro selection and molecular characterisation of human immunodeficiency virus-1 resistant to nonnucleoside inhibitors of reverse transcriptase. Mol Pharmacol 1992; 41: 446–51.
Nunberg J14, Schleif WA, Boots EJ, et al. Viral resistance to human immunodeficiency virus type-lspecific pyridinone reverse transcriptase inhibitors. J Virol 1991; 65: 4887–92.
Richman D, Rosenthal AS, Skoog M, et al. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 1991, 35; 305–8.
Richman DD, Havlir D, Corbeil. Nevirapine resistance mutations of human immunodeficiency virus (HIV) type 1 selected during therapy. J Virol 1994; 68: 1660–6.
Cheeseman SH. Havlir D. McLaughlin MM, et al. Phase I/1I evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immun Defic Syndrom Related Retrovir 1995; 8: 141–51.
Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537–45.
Larder BA. 3’-azido-3’-deoxythymidine resistance suppressed by a mutation conferring human immunodefiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992; 36: 2664–9.
Richman DD. Nevirapine resistance during clinical trials (abstract). In: Abstracts of the Second International Workshop on HIV Drug Resistance; Noordwijk, June 1993: 26.
Carr A Vasak E, Munro V, Penny R, Cooper DA. Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection. Clin Exp Immunol 1994; 97: 250–3.
de Jong MD, Loewenthal M, Boucher CAB, et al. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity. J Infect Dis 1994; 169: 1346–50.
de Jong M, and the Dutch-Italian-Australian Nevirapine Study Group. Antiviral response to nevirapine monotherapy in nucleoside naive persons. In: Abstracts of the 10th International Conference on AIDS, Yokohama, Japan, August, 1994; Abstract PB0847.
Can A, and the Australian-Italian-Dutch Nevirapine Study Group. Efficacy of nevirapinn added to zidovudine in p24-positive HIV-1-infected patients with CD4+ counts less than 500/nun. In: Abstracts of the 10th International Conference on AIDS, Yokohama, Japan, August, 1994; Abstract 511B.
Fischi MA. Efficacy and toxicities of combination antiretroviral therapies. In: Program of the 2nd International Congress on Drug Therapy of HIV Infection, Glasgow, United Kingdom, November, 1994: Abstract 7. 2.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Carr, A., Cooper, D.A. (1996). Current Clinical Experience with Nevirapine for HIV Infection. In: Mills, J., Volberding, P.A., Corey, L. (eds) Antiviral Chemotherapy 4. Advances in Experimental Medicine and Biology, vol 394. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9209-6_27
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9209-6_27
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9211-9
Online ISBN: 978-1-4757-9209-6
eBook Packages: Springer Book Archive